BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 3,180 shares, a decline of 64.9% from the October 15th total of 9,051 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 3,299 shares, the short-interest ratio is currently 1.0 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings cut shares of BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company has an average rating of “Sell”.
Read Our Latest Stock Analysis on BGLC
BioNexus Gene Lab Price Performance
Shares of BGLC traded down $0.12 during mid-day trading on Monday, hitting $0.79. The company’s stock had a trading volume of 251 shares, compared to its average volume of 38,500. BioNexus Gene Lab has a 1-year low of $0.81 and a 1-year high of $4.97. The company has a current ratio of 6.08, a quick ratio of 5.28 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $2.32 million, a P/E ratio of -0.63 and a beta of 4.28. The firm has a 50-day simple moving average of $1.22 and a 200 day simple moving average of $1.86.
BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.12) EPS for the quarter. BioNexus Gene Lab had a negative return on equity of 32.92% and a negative net margin of 82.38%. The company had revenue of $0.08 million for the quarter.
About BioNexus Gene Lab
BioNexus Gene Lab Corp. is a Malaysia-focused company with businesses in medical diagnostics and chemical distribution. Through its laboratory operations, it provides molecular and genetic testing services to support healthcare assessment and decision-making. The company also distributes industrial and specialty chemicals through its subsidiary, Chemrex Corporation. Its products serve business customers in sectors that use chemicals in manufacturing and related applications. BioNexus Gene Lab’s operations are primarily based in Malaysia.
Further Reading
- Five stocks we like better than BioNexus Gene Lab
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
